Advances on the treatment of Dyslipidaemias
Treatment targets for Low Density Lipoprotein Cholesterol (LDL-C), according to the recently published guidelines, are low enough and a substantial proportion of patients are unable to reach them. A new class of hypolipidaemic medications, proprotein convertase subtilisin/kexin type 9 inhibitors (PC...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | ell |
| Published: |
Scientific Council of the General Hospital of Piraeus Tzaneion
2017-01-01
|
| Series: | Epistīmonika Chronika |
| Subjects: | |
| Online Access: | http://www.tzaneio.gr/images/docs/S1-15.pdf |